Leading science, pioneering therapies

Neural stem cells and brain cancer group publications

2018

Dewari PSingh, Southgate B, Mccarten K, Monogarov G, O'Duibhir E, Quinn N, Tyrer A, Leitner M-C, Plumb C, Kalantzaki M et al..  2018.  An efficient and scalable pipeline for epitope tagging in mammalian stem cells using Cas9 ribonucleoprotein.Elife. 7

2017

Ingallina C, Costa PM, Ghirga F, Klippstein R, Wang JT, Berardozzi S, Hodgins N, Infante P, Pollard SM, Botta B et al..  2017.  Polymeric glabrescione B nanocapsules for passive targeting of Hedgehog-dependent tumor therapy in vitro.Nanomedicine (Lond). 12(7):711-728.
Martella A, Matjusaitis M, Auxillos J, Pollard SM, Cai Y.  2017.  EMMA: An Extensible Mammalian Modular Assembly Toolkit for the Rapid Design and Production of Diverse Expression Vectors.ACS Synth Biol.
Garcia I, Aldaregia J, Vicentic JMarjanovic, Aldaz P, Moreno-Cugnon L, Torres-Bayona S, Carrasco-Garcia E, Garros-Regulez L, Egaña L, Rubio A et al..  2017.  Oncogenic activity of SOX1 in glioblastoma.Sci Rep. 7:46575.
Bulstrode H, Johnstone E, Marqués-Torrejón MÁngeles, Ferguson KM, Bressan RBardini, Blin C, Grant V, Gogolok S, Gangoso E, Gagrica S et al..  2017.  Elevated FOXG1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional control of cell cycle and epigenetic regulators.Genes Dev. 31(8):757-773.
Bressan RBardini, Dewari PSingh, Kalantzaki M, Gangoso E, Matjusaitis M, Garcia-Diaz C, Blin C, Grant V, Bulstrode H, Gogolok S et al..  2017.  Efficient CRISPR/Cas9-assisted gene targeting enables rapid and precise genetic manipulation of mammalian neural stem cells.Development. 144(4):635-648.

2016

Blake SM, Stricker SH, Halavach H, Poetsch AR, Cresswell G, Kelly G, Kanu N, Marino S, Luscombe NM, Pollard SM et al..  2016.  Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation.Elife. 5
Krusche B, Ottone C, Clements MP, Johnstone ER, Goetsch K, Lieven H, Mota SG, Singh P, Khadayate S, Ashraf A et al..  2016.  EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells.Elife. 5
Gogolok S, Garcia-Diaz C, Pollard SM.  2016.  STAR: a simple TAL effector assembly reaction using isothermal assembly.Sci Rep. 6:33209.
Pollard SM.  2016.  Quantitative stem cell biology: the threat and the glory.Development. 143(22):4097-4100.
Okawa S, Gagrica S, Blin C, Ender C, Pollard SM, Krijgsveld J.  2016.  Proteome and Secretome Characterization of Glioblastoma-Derived Neural Stem Cells.Stem Cells.
Carén H, Beck S, Pollard SM.  2016.  Differentiation therapy for glioblastoma – too many obstacles?Molecular & Cellular Oncology. 3(2):e1124174.
Martella A, Pollard SM, Dai J, Cai Y.  2016.  Mammalian Synthetic Biology: Time for Big MACs.ACS Synth Biol.
Garros-Regulez L, Aldaz P, Arrizabalaga O, Moncho-Amor V, Carrasco-Garcia E, Manterola L, Moreno-Cugnon L, Barrena C, Villanua J, Ruiz I et al..  2016.  mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.Expert Opin Ther Targets. 20(4):393-405.
Pollard SM, M Marqués-Torrejón Á.  2016.  Give it a REST!Elife. 5

2015

Carén H, Stricker SH, Bulstrode H, Gagrica S, Johnstone E, Bartlett TE, Feber A, Wilson G, Teschendorff AE, Bertone P et al..  2015.  Glioblastoma Stem Cells Respond to Differentiation Cues but Fail to Undergo Commitment and Terminal Cell-Cycle Arrest.Stem Cell Reports.
Toledo CM, Ding Y, Hoellerbauer P, Davis RJ, Basom R, Girard EJ, Lee E, Corrin P, Hart T, Bolouri H et al..  2015.  Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells.Cell Rep.

2014

2013

Sofueva S, Yaffe E, Chan W-C, Georgopoulou D, Rudan MVietri, Mira-Bontenbal H, Pollard SM, Schroth GP, Tanay A, Hadjur S.  2013.  Cohesin-mediated interactions organize chromosomal domain architecture.EMBO J. 32(24):3119-29.

Pages